Resistance-associated mutation prevalence according to subtypes B and non-B of HIV type 1 in antiretroviral-experienced patients in minas Gerais, Brazil

AIDS Research and Human Retroviruses

Volumn 27, Issue 9, 2011, Pages 981-987

  Westin, Mateus R ^a   Biscione, Fernando M ^a   Fonseca, Marise ^a   Ordones, Monique ^a   Rodrigues, Mirian ^a   Greco, Dirceu B ^a   Tupinambas, Unai ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEROTYPE; VIRUS MUTATION;

ADULT; AGED; ANTI-HIV AGENTS; BRAZIL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PREVALENCE;

EID: 80052065930     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0260     Document Type: Article

References (33)

1. Marins JR, Jamal LF, Chen SY, et al.: Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17:1675-1682. (Pubitemid 36951688)
2. Puhan MA, Van Natta ML, Palella FJ, Addessi A, and Mei-nert C: Ocular Complications of AIDS Research Group. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: Temporal changes and risk factors. Clin Infect Dis 2010;51:947-956.
3. Ministério da Saúde-Brasil: Programa Nacional DST/AIDS. Recomendaçoes para terapia antiretroviral em adultos e adolescentes infectados pelo HIV, 2008. Available at www.aids.gov.br/renageno.
4. Hirsch MS, Gunthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adults with HIV infection: 2008 recommendations of an International AIDS Society-USA Painel. Clin Infect Dis 2008;47:266-285. (Pubitemid 351920631)
5. Shafer RW and Schapiro JM: HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 2008;10:67-84.
6. Costagliola D, Descamps D, Assoumou L, et al.: Prevalence of HIV-1 drug resistance in treated patients: A French nationwide study. J Acquir Immune Defic Syndr 2007;46:12-18. (Pubitemid 47507429)
7. Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, et al.: Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: Assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2005;100:73-78.
8. Cavalcanti AMS, Lacerda HR, Brito AM, Pereira S, Medeiros D, and Oliveira S: Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the northeast region of Brazil. Mem Inst Oswaldo Cruz 2007;102:785-792. (Pubitemid 350248734)
9. Ma L, Sun J, Xing H, et al.: Genotype and phenotype patterns of drug-resistant HIV-1 subtype B (Thai B) Isolated from patients failing antiretroviral therapy in China. J Acquir Immune Defic Syndr 2007;44:14-19. (Pubitemid 46052215)
10. García-Guerrero J, Sáiz de la Hoya P, Portilla J, et al.: Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates. Eur J Clin Microbiol Infect Dis 2006;25:695-701. (Pubitemid 44806777)
11. Hogg RS, Bangsberg DR, Lima VD, et al.: Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006;3:e356.
12. Recsky MA, Brumme ZL, Chan KJ, et al.: Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004;190:285-292. (Pubitemid 38951968)
13. Lucas GM, Gallant JE, and Moore RD: Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 2004;18:1539-1548. (Pubitemid 39037478)
14. Munerato P, Sucupira MC, Oliveiros MP, et al.: HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the city of Sao Paulo, Brazil. AIDS Res Hum Retroviruses 2010; 26:265-272.
15. Zaccarelli M, Tozzi V, Lorenzini P, et al.: Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005;19:1081-1089. (Pubitemid 40961149)
16. Zaccarelli M, Tozzi V, Lorenzini P, et al.: The V118I mutation as a marker of advanced HIV infection and disease progression. Antivir Ther 2007;12:163-168. (Pubitemid 46569901)
17. Martfnez-Cajas JL, Pant-Pai N, Klein MB, and Wainberg MA: Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence. AIDS Rev 2008;10:212-223.
18. Holguín A, López M, and Soriano V: Reliability of rapid subtyping tools compared to that of phylogenetic analysis for characterization of human immunodeficiency virus type 1 non-B subtypes and recombinant forms. J Clin Microbiol 2008;46:3896-3899.
19. Yebra G, de Mulder M, Martin L, et al.: Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of näive HIV-infected patients (CoRIS). Antiviral Res 2011;89:19-25.
20. Brindeiro RM, Diaz RS, Sabino EC, et al.: Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): A survey of chronically infected individuals. AIDS 2003;17:1063-1069. (Pubitemid 36549719)
21. Cerqueira DM, Amorim RM, Silva RR, Camara GN, Brfgido MM, and Martins CR: Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 2004;99:877-882. (Pubitemid 40248988)
22. Araujo AD, Brites C, Monteiro-Cunha J, Santos LA, Galvao-Castro B, and Alcantara LC: Lower prevalence of human imunodeficiency virus type 1 Brazilian subtype B found in northeastern Brazil with slower progression to AIDS. AIDS Res Hum Retroviruses 2010;26:1249-1254.
23. De Sa-Filho DJ, Ambar RF, Duarte NB, et al.: HIV type 1 diversity from newly diagnosed patients in Santos Metropolitan Area/Brazil. AIDS Res Hum Retroviruses 2009;25:925-929.
24. Cardoso LP, Queiroz BB, and Stefani MM: HIV-1 pol phy-logenetic diversity and antiretroviral resistance mutations in treatment naïve patients from central west Brazil. J Clin Virol 2009;46:134-139.
25. Soares EA, Martinez AM, Souza TM, et al.: HIV-1 subtype C dissemination in southern Brazil. AIDS 2005;19:S81-S86. (Pubitemid 41668992)
26. Da Silva MM, Telles FQ, da Cunha CA, and Rhame FS: HIV subtype, epidemiological and mutational correlations in patients from Paraná, Brazil. Braz J Infect Dis 2010;14(5):495-501.
27. Inocencio LA, Pereira AA, Sucupira MC, et al.: Brazilian Network for HIV Drug Resistance Surveillance: A survey of individuals recently diagnosed with HIV. J Int AIDS Soc 2009;12:20.
28. Brigido LF, Ferreira JL, Almeida VC, et al.: Southern Brazil HIV type 1 C expansion into the State of Sao Paulo, Brazil. AIDS Res Human Retroviruses Online Ahead of Print: October 15, 2010. doi:10.1089/aid.2010.0157.
29. De Sa-Filho DJ, Soares MS, Candido V, et al.: HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil. AIDS Res Hum Retroviruses 2008;24:347-353. (Pubitemid 351457749)
30. Ferreira FGF, Pinto JA, Kakehasi FM, et al.: Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically infected children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses 2010;26:229-232.
31. Tupinambás U, Aleixo A, and Greco DB: HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment. Braz J Infect Dis 2005;9:324-329. (Pubitemid 43141337)
32. Kantor R and Katzenstein D: Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003;5:25-35. (Pubitemid 36873892)
33. Kantor R, Katzenstein DA, Efron B, et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2:e112.